by Novadip | Jun 25, 2025 | Featured News
SpinalSurgeryNews – 25 June 2025 Dr. Denis Dufrane co-founded Novadip in 2013 and joined the company as Chief Scientific Officer in 2015 before being appointed CEO. Prior to joining Novadip on a full-time basis, Dr. Dufrane was head of both the Musculoskeletal...
by Novadip | Jun 23, 2025 | Press Releases
Novadip is developing NVD003, an autologous therapy derived from adipose stem cells, as a potential single treatment to save limbs and restore mobility in patients with CPT. The RMAT designation is part of the IND that Novadip obtained for NVD003, with plans to reach...
by Novadip | Apr 29, 2025 | Press Releases
No refractures were reported during long-term follow-up at five years At 24-months post-implantation, 89% of patients achieved bone union Novadip plans market launch of NVD003 in 2027 Mont Saint-Guibert, Belgium, April 29, 2025 – Novadip Biosciences, a late-stage...
by Novadip | Apr 22, 2025 | Press Releases
NVDX3 elicited bone formation as early as 12 weeks and functional fusion by 26 weeks in ovine posterolateral fusion (PLF) model In phase 1b/2a clinical trial, early bone fusion was observed at 12 months, coupled with no NVDX3-related adverse events, in patients who...
by Novadip | Apr 2, 2025 | Press Releases
Seasoned leader with solid experience in senior international finance roles joins Novadip at pivotal time to support ambitious Series C roundAppointment further strengthens expert C-suite team to drive clinical advancements and path to commercialization by 2027. Mont...